Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (688505) Fair Value & Analysis
Healthcare · CN · Market cap 7.1B CNY
Fair value as of: Jun 24, 2026
Analysis
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (688505) currently trades at ¥7.22, while our model-based Fair Value estimate is ¥13.55 — implying the stock looks roughly 87.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (688505) undervalued?
What is the fair value of 688505?
What is the quality score of 688505?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.